v3.26.3
Financial Income, Net
9 Months Ended
Sep. 30, 2026
Financial Income, Net [Abstract]  
FINANCIAL INCOME, NET

NOTE 15 - FINANCIAL INCOME, NET:

 

    Nine months ended     Three months ended  
    September 30,
2026
    September 30,
2025
    September 30,
2026
    September 30,
2025
 
Revaluation of investments:                        
Revaluation of Scilex, net (see note 4)     (3,428 )     38,457       (5,895 )     34,163  
Revaluation of Hapisga, net (see note 7)     9,441       853       (537 )     418  
Revaluation of Alpha Tau, net (see note 8)     174,500       29,691       41,083       22,306  
Revaluation of RoyaltyVest loan, net (see note 6)     (549 )     294       (444 )     1,324  
Revaluation of Profit Sharing Loan Agreement (see note 4)     193       161       196       64  
Revaluation of Ruby Capital (see note 4)     (50 )     -       (15 )     -  
Revaluation of Lifeward (see note 8) (1)     1,140       -       (3,927 )     -  
Revaluation of 83 Wythe Loan and Warren at Bay Loan (see note 4)     (424 )     -       (64 )     -  
Revaluation of Marketable Securities (see note 3)     (1,911 )     2,786       147       2,686  
    $ 178,912     $ 72,242     $ 30,544     $ 60,961  
Loan extension fee income – Scilex (see note 4)     1,000       -       1,000       -  
Interest Income     524       2,135       150       510  
Exchange rate     (127 )     106       (81 )     (8 )
Other     180       (205 )     284       7  
      180,489       74,278       31,897       61,470  

 

(1) For the nine months ended September 30, 2026, includes revaluation gains of $88 on the Lifeward shares and $3,655 on the Lifeward warrants, offset by a revaluation loss of $1,144 on the Initial Note and a loss of $1,459 recognized upon the conversion of the Secured Promissory Note and the additional note into the Initial Note.

 

For the three months ended September 30, 2026, includes revaluation losses of $1,325 on the Lifeward shares and $1,448 on the Lifeward warrants, and a revaluation loss of $1,154 on the Initial Note (see note 8).